Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Caliway Biopharmaceuticals Co (TPE:6919) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Caliway Biopharmaceuticals Co Net Margin % Related Terms
Caliway Biopharmaceuticals Co Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6919 vs VRTX, REGN, MRNA: Net Margin % Comparison
For the Biotechnology subindustry, Caliway Biopharmaceuticals Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Caliway Biopharmaceuticals Co Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Caliway Biopharmaceuticals Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where Caliway Biopharmaceuticals Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Caliway Biopharmaceuticals Co (TPE:6919) has a Net Margin % of -6,239.93% as of Jun. 2026. Net margin is the ratio of total net income to net sales. View historical data on Caliway Biopharmaceuticals Co and its competitors. According to the industry distribution chart, Caliway Biopharmaceuticals Co ranks #741 out of 945 companies in the Biotechnology industry, placing it in the top 78.4%.
Is Caliway Biopharmaceuticals Co's Net Margin % too high?
Caliway Biopharmaceuticals Co's current Net Margin % is -6,239.93%. Based on the distribution chart, Caliway Biopharmaceuticals Co ranks #741 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Caliway Biopharmaceuticals Co has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Caliway Biopharmaceuticals Co's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Caliway Biopharmaceuticals Co ranks #741 out of 945 companies for Net Margin %. This places Caliway Biopharmaceuticals Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Caliway Biopharmaceuticals Co and its competitors. Caliway Biopharmaceuticals Co's current Net Margin % is -6,239.93%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caliway Biopharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Caliway Biopharmaceuticals Co (TPE:6919) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$59.00, compared to a current price of NT$94.80 — trading 60.7% above its estimated fair value. The current Net Margin % is -6,239.93%. Caliway Biopharmaceuticals Co's overall GF Score™ is 55/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Caliway Biopharmaceuticals Co (TPE:6919), the current Net Margin % is -6,239.93% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Caliway Biopharmaceuticals Co (TPE:6919) Overvalued in 2026?
Based on GuruFocus' analysis, Caliway Biopharmaceuticals Co stock appears to be overvalued.
The current stock price of NT$94.80 is trading 60.7% above its estimated GF Value™ of NT$59.00.
GuruFocus considers Caliway Biopharmaceuticals Co to be Significantly Overvalued.
Key valuation signals for TPE:6919:
Net Margin %: -6,239.93%
GF Value™: NT$59.00 vs. price of NT$94.80 (60.7% above fair value)
No single metric tells the full story. See the TPE:6919 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Caliway Biopharmaceuticals Co Ltd specializes in the development of new drugs for aesthetic medicine and chronic inflammation. The group has one operating segment, which is Healthy Food, and others.
55GF Score
Get the complete analysis for TPE:6919
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6919 has been successfully added to your 
